Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
2.930
-0.150 (-4.87%)
Nov 21, 2024, 10:59 AM EST - Market open

Climb Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Income
-69.12-35.12-45.24-47.48-20.67-6.55
Asset Writedown & Restructuring Costs
51.660.18--9.162.75
Loss (Gain) From Sale of Investments
-0.58-2.33-0.180.37--
Stock-Based Compensation
5.112.816.993.740.71-
Other Operating Activities
0.510.10.8511.47-0.36-0.9
Change in Accounts Payable
-2.05-0.69-0.650.32-0.020.02
Change in Other Net Operating Assets
3.54.450.86-4.49-2.91-0.33
Operating Cash Flow
-10.99-20.6-37.37-36.07-14.1-5.01
Cash Acquisitions
-4.65---8.28-
Sale (Purchase) of Intangibles
-----0.2-
Investment in Securities
-21.2968.9834.44-114.97--
Investing Cash Flow
-30.9468.9834.44-114.978.08-
Issuance of Common Stock
130.980.84-83.29--
Financing Cash Flow
130.980.84-177.234.9326.24
Foreign Exchange Rate Adjustments
-0.230.3-0.410.250.36-0.01
Net Cash Flow
88.8249.53-3.3426.44-0.7421.22
Free Cash Flow
-10.99-20.6-37.37-36.07-14.1-5.01
Free Cash Flow Per Share
-0.29-0.76-1.42-2.94-6.44-3.02
Levered Free Cash Flow
-39.253.46-20.51-25.3-6.57-
Unlevered Free Cash Flow
-39.253.46-20.51-25.3-6.57-
Change in Net Working Capital
-1.61-4.07-0.716.74-0.28-
Source: S&P Capital IQ. Standard template. Financial Sources.